Viridian Therapeutics, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Viridian Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 20, 2026). It closed at $22.82, 32.4% below its 52-week high and above its 200-day average, which is falling.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. More about the company

$22.82

+0.35% today

$2.6B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VRDN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 16w

S4 14w

S2 26w

S1 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 8w → S2 5w → S3 5w → S4 16w → S1 8w → S2 11w → S3 12w → S4 14w → S1 10w → S2 26w → S3 8w → S4 11w → S1 15w → S4 1w current

Total tracked: 166 weeks across 15 stage runs.

VRDN among Biotechnology201st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…201	VRDNViridian Therapeutics, Inc.	Stage 4 · wk 1	50	+6.5%

vs 52W High

-32.4%

$13.30 lo$33.78 hi

32.4% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

3.8%

200 DMA: $21.99 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.89x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+6.5%

+18.4%

+60.4%

YTD

-25.6%

-5.0%

Scan Membership

Breakout Watch

Latest: 2024-09-26

10 appearances in last 60 days. First seen: 2020-06-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.89x

2026-10-21S4

Wk 1 · Vol 0.88x

2026-10-20S41→4

Wk 1 · Vol 1.12x

2026-10-19S1

Wk 15 · Vol 1.47x

2026-10-16S1

Wk 15 · Vol 1.38x

2026-10-15S1

Wk 15 · Vol 1.22x

2026-10-14S1

Wk 15 · Vol 2.14x

2026-10-13S1

Wk 14 · Vol 1.22x

2026-10-12S1

Wk 14 · Vol 1.13x

2026-10-09S1

Wk 14 · Vol 0.78x

2026-10-08S1

Wk 14 · Vol 1.43x

2026-10-07S1

Wk 14 · Vol 1.00x

Moving averages & range

50 DMA

$21.59

200 DMA

$21.99

52W High

$33.78

52W Low

$13.30

5D Low

$19.03

Resistance levels (recent highs)

20d High

$22.82

60d High

$24.80

120d High

$24.80

250d High

$33.78

Next resistance

+8.7%

to 60d High

ROE

-65.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 4.6

Viridian Therapeutics: quick answers

What stage is Viridian Therapeutics in?

As of Oct 22, 2026, Viridian Therapeutics (VRDN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is Viridian Therapeutics in an uptrend?

No. Viridian Therapeutics is in a Stage 4 downtrend. It trades 3.8% above its 200-day average, which is falling.

How far is Viridian Therapeutics from its 52-week high?

Viridian Therapeutics closed at $22.82 on Oct 22, 2026, 32.4% below its 52-week high of $33.78. Its 52-week low is $13.30.

How has Viridian Therapeutics performed over the past year?

As of Oct 22, 2026, Viridian Therapeutics is down 5.0% over the past year and down 25.6% so far in 2026.

Which sector and industry is Viridian Therapeutics in?

Viridian Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.